JCR Pharmaceuticals Co., Ltd. announced appointment of Pascal Yoshida, M.D. as Senior Director, Head of Medical Affairs Unit, effective from July 1, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
577 JPY | +0.52% | +2.49% | -50.77% |
May. 31 | JCR Pharmaceuticals' Full-Year Profit Up 46% | MT |
May. 27 | Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 560 Yen From 1,200 Yen, Keeps at Hold | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.77% | 456M | |
+42.15% | 739B | |
+32.34% | 598B | |
-6.01% | 353B | |
+17.26% | 318B | |
+3.28% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+5.62% | 164B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Appoints Pascal Yoshida as Senior Director, Head of Medical Affairs Unit